William J. Gradishar, MD, on the Therapeutic Shift in Managing HR-Positive, HER2-Negative Breast Cancer

Posted: Monday, April 22, 2024

William J. Gradishar, MD, of Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses the science behind trends of improved outcomes for patients with breast cancer, both early- and late-stage, which is largely the result of the integration of new drugs partnered with endocrine therapy. This approach is changing the contour of how patients are treated today.

---